Immunotherapy targeting colon cancer stem cells

Immunotherapy

Volumn 3, Issue 1, 2011, Pages 97-106

  Iovino, Flora ^a   Meraviglia, Serena ^b   Spina, Marisa ^a   Orlando, Valentina ^b   Saladino, Vitanna ^b   Dieli, Francesco ^b   Stassi, Giorgio ^a,c   Todaro, Matilde ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c IRCCS   (Italy)

Author keywords

T cells; cancer stem cells; chemoresistance; immunotherapy; NK cell

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOBISPHOSPHONATE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACTIVE IMMUNIZATION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CELL THERAPY; COLON CANCER; GAMMA DELTA T LYMPHOCYTE; HUMAN; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

COLONIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASTIC STEM CELLS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 78650568825     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.87     Document Type: Review

References (86)

1. Lapidot T, Sirard C, Vormoor J et al.: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464), 645-648 (1994). n One of the first investigations concerning cancer-initiating cells. (Pubitemid 24067706)
2. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997). (Pubitemid 27298715)
3. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003). (Pubitemid 36418143)
4. O'brien C, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123), 106-110 (2007). (Pubitemid 46067310)
5. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123), 111-115 (2007). (Pubitemid 46067311)
6. Barker N, Ridgway RA, Van Es JH et al.: Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457(7229), 608-611 (2009).
7. Liu S, Dontu G, Mantle ID et al.: Hedgehog signaling and BMI-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66(12), 6063-6071 (2006).
8. Ginestier C, Hur MH, Charafe-Jauffret E et al.: ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007). (Pubitemid 350056407)
9. Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, Stassi G: Therapeutic implications of cancer initiating cells. Expert Opin. Biol. Ther. 9(8), 1005-1016 (2009).
10. Dean M, Fojo T, Bates S: Tumor stem cells and drug resistance. Nat. Rev. Cancer 5(4), 275-284 (2005). (Pubitemid 40488633)
11. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G: IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 7(3), 309-313 (2008). (Pubitemid 351366493)
12. Bauer N, Fonseca AV, Florek M et al.: New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 188(1-2), 127-138 (2008). (Pubitemid 351962236)
13. Zhu L, Gibson P, Currle DS et al.: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457(7229), 603-607 (2009).
14. Liu S, Dontu G, Wicha MS: Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7(3), 86-95 (2005). (Pubitemid 40704127)
15. Vermeulen L, Todaro M, De Sousa Mello F et al.: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl Acad. Sci. USA 105(36), 13427-13432 (2008). n Highlights colon cancer stem cell properties.
16. Charafe-Jauffret E, Ginestier C, Iovino F et al.: Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69(4), 1302-1313 (2009).
17. Charafe-Jauffret E, Ginestier C, Iovino F et al.: Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16(1), 45-55
18. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S: Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11(4), R46 (2009).
19. Balic M, Lin H, Young L et al.: Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12(19), 5615-5621 (2006). (Pubitemid 44629587)
20. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Invest. 112(12), 1776-1784 (2003). (Pubitemid 38063698)
21. Hugo H, Ackland ML, Blick T et al.: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell Physiol. 213(2), 374-383 (2007). (Pubitemid 47509716)
22. Sarkar D, Dent P, Curiel DT, Fisher PB: Acquired and innate resistance to the cancer-specific apoptosis-inducing cytokine, MDA-7/IL-24: not insurmountable therapeutic problems. Cancer Biol. Ther. 7(1), 109-112 (2008). (Pubitemid 351590462)
23. Storci G, Sansone P, Trere D et al.: The basal-like breast carcinoma phenotype is regulated by slug gene expression. J. Pathol. 214(1), 25-37 (2008).
24. Turley EA, Veiseh M, Radisky DC, Bissell MJ: Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5(5), 280-290 (2008). (Pubitemid 351594144)
25. Eliane JP, Repollet M, Luker KE et al.: Monitoring serial changes in circulating human breast cancer cells in murine xenograft models. Cancer Res. 68(14), 5529-5532 (2008).
26. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T: Opinion: migrating cancer stem cells - an integrated concept of malignant tumor progression. Nat. Rev. Cancer 5(9), 744-749 (2005). (Pubitemid 41486367)
27. Briegel KJ: Embryonic transcription factors in human breast cancer. IUBMB Life 58(3), 123-132 (2006). (Pubitemid 43786037)
28. Hartwell L, Mankoff D, Paulovich A, Ramsey S, Swisher E: Cancer biomarkers: a systems approach. Nat. Biotechnol. 24(8), 905-908 (2006). (Pubitemid 44215377)
29. Peinado H, Olmeda D, Cano A: Snail, zeb and bhlh factors in tumor progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 7(6), 415-428 (2007). (Pubitemid 46809165)
30. Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD: Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl Acad. Sci. USA 105(39), 14867-14872 (2008).
31. Dimeo TA, Anderson K, Phadke P et al.: A novel lung metastasis signature links wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69(13), 5364-5373 (2009).
32. Kurrey NK, Jalgaonkar SP, Joglekar AV et al.: Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27(9), 2059-2068 (2009).
33. Mani SA, Guo W, Liao MJ et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704-715 (2008). (Pubitemid 351636299)
34. Roussos ET, Keckesova Z, Haley JD, Epstein DM, Weinberg RA, Condeelis JS: AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 70(19), 7360-7364 (2010).
35. Todaro M, Lombardo Y, Francipane MG et al.: Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 15(4), 762-772 (2008). (Pubitemid 351405081)
36. Stefano AB, Iovino F, Lombardo Y et al.: Survivin is regulated by interleukin-4 in colon cancer stem cells. J. Cell Physiol. 225(2), 555-561 (2010).
37. + melanoma cells. Cancer Immunol. Immunother. 58(10), 1635-1646 (2009).
38. Sigalotti L, Covre A, Zabierowski S et al.: Cancer testis antigens in human melanoma stem cells: expression, distribution, and methylation status. J. Cell Physiol. 215(2), 287-291 (2008). (Pubitemid 351468940)
39. Adair SJ, Hogan KT: Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother. 58(4), 589-601 (2009).
40. Uchida N, Buck DW, He D et al.: Direct isolation of human central nervous system stem cells. Proc. Natl Acad. Sci. USA 97(26), 14720-14725 (2000). (Pubitemid 32016642)
41. Todaro M, Alea M., Di Stefano AB et al.: Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1(4), 389-402 (2007). n Highlights the expression of IL-4 in colon cancer stem cells. (Pubitemid 47506537)
42. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ: TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol. Cell Biol. 84(1), 87-98 (2006).
43. Nebbioso A, Clarke N, Voltz E et al.: Tumor-selective action of hdac inhibitors involves trail induction in acute myeloid leukemia cells. Nat. Med. 11(1), 77-84 (2005). (Pubitemid 40215841)
44. Corvaisier M, Moreau-Aubry A, Diez E et al.: Vγ9vδ 2 T cell response to colon carcinoma cells. J. Immunol. 175(8), 5481-5488 (2005). (Pubitemid 41456435)
45. + T cells into human colorectal cancer: flow cytometric analysis of TCR-γ δ expression in tumour-infiltrating lymphocytes. Clin. Exp. Immunol. 102(1), 167-173 (1995).
46. Girardi M, Oppenheim DE, Steele CR et al.: Regulation of cutaneous malignancy by γδ T cells. Science 294(5542), 605-609 (2001).
47. + γδ-T cells mediate innate antitumor activity against human prostate cancer cells in vitro. J. Urol. 173(5), 1552-1556 (2005). (Pubitemid 40524770)
48. Kabelitz D, Wesch D, Pitters E, Zoller M: Characterization of tumor reactivity of human Vγ9Vδ2 γδ T cells in vitro and in scid mice in vivo. J. Immunol. 173(11), 6767-6776 (2004). (Pubitemid 39541063)
49. Bonneville M, Scotet E: Human Vγ9Vδ2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18(5), 539-546 (2006). (Pubitemid 44311448)
50. D'asaro M, La Mendola C, Di Liberto D et al.: Vγ9Vδ 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J. Immunol. 184(6), 3260-3268 (2010).
51. Green JR: Antitumor effects of bisphosphonates. Cancer 97(Suppl. 3), 840-847 (2003).
52. Clezardin P, Ebetino FH, Fournier PG: Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res. 65(12), 4971-4974 (2005). (Pubitemid 40827299)
53. Das H, Wang L, Kamath A, Bukowski JF: Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98(5), 1616-1618 (2001).
54. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G: Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197(2), 163-168 (2003). (Pubitemid 36152311)
55. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N: Targeting of tumor cells for human γδ T cells by nonpeptide antigens. J. Immunol. 167(9), 5092-5098 (2001). (Pubitemid 33009743)
56. Mattarollo SR, Kenna T, Nieda M, Nicol AJ: Chemotherapy and zoledronate sensitize solid tumour cells to Vγ9Vδ2 T cell cytotoxicity. Cancer Immunol. Immunother. 56(8), 1285-1297 (2007). (Pubitemid 46763941)
57. Sato K, Kimura S, Segawa H et al.: Cytotoxic effects of γδ T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int. J. Cancer 116(1), 94-99 (2005). (Pubitemid 40827760)
58. Girlanda S, Fortis C, Belloni D et al.: Mica expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated γδ lymphocytes. Cancer Res. 65(16), 7502-7508 (2005). (Pubitemid 41161286)
59. Dalton JE, Howell G, Pearson J, Scott P, Carding SR: Fas-Fas ligand interactions are essential for the binding to and killing of activated macrophages by γδ T cells. J. Immunol. 173(6), 3660-3667 (2004). (Pubitemid 39280726)
60. Viey E, Fromont G, Escudier B et al.: Phosphostim-activated γδ T cells kill autologous metastatic renal cell carcinoma. J. Immunol. 174(3), 1338-1347 (2005). (Pubitemid 46638760)
61. Carding SR, Egan PJ: γδ T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2(5), 336-345 (2002).
62. Ismaili J, Olislagers V, Poupot R, Fournie JJ, Goldman M: Human γδ T cells induce dendritic cell maturation. Clin. Immunol. 103(3 Pt 1), 296-302 (2002). (Pubitemid 34666753)
63. Casetti R, Perretta G, Taglioni A et al.: Drug-induced expansion and differentiation of Vγ9Vδ 2 T cells in vivo: the role of exogenous IL-2. J. Immunol. 175(3), 1593-1598 (2005). (Pubitemid 41023061)
64. Kobayashi H, Tanaka Y, Yagi J et al.: Safety profile and anti-tumor effects of adoptive immunotherapy using γδ T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol. Immunother. 56(4), 469-476 (2007). (Pubitemid 46204533)
65. Todaro M, D'asaro M, Caccamo N et al.: Efficient killing of human colon cancer stem cells by γδ T lymphocytes. J. Immunol. 182(11), 7287-7296 (2009). n Suggested that γδ T lymphocytes kill colon cancer stem cells.
66. Moretta L, Moretta A: Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 23(2), 255-259 (2004). (Pubitemid 38294490)
67. Moretta A, Bottino C, Vitale M et al.: Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14, 619-648 (1996). (Pubitemid 26130196)
68. Moretta A, Bottino C, Vitale M et al.: Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 19, 197-223 (2001). (Pubitemid 32368034)
69. Garrido F, Ruiz-Cabello F, Cabrera T et al.: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 18(2), 89-95 (1997). (Pubitemid 27107103)
70. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S: Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74, 181-273 (2000).
71. Maleno I, Lopez-Nevot MA, Cabrera T, Salinero J, Garrido F: Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol. Immunother. 51(7), 389-396 (2002). (Pubitemid 35002044)
72. Rodriguez T, Mendez R, Roberts CH et al.: High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. Cancer Immunol. Immunother. 54(2), 141-148 (2005). (Pubitemid 40100836)
73. Perez B, Benitez R, Fernandez MA et al.: A new b2 microglobulin mutation found in a melanoma tumor cell line. Tissue Antigens 53(6), 569-572 (1999). (Pubitemid 29257768)
74. Mendez R, Rodriguez T, Del Campo A et al.: Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol. Immunother. 57(5), 719-729 (2008). (Pubitemid 351641032)
75. Seliger B, Atkins D, Bock M et al.: Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin. Cancer Res. 9(5), 1721-1727 (2003). (Pubitemid 36554596)
76. + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein. J. Exp. Med. 171(3), 667-679 (1990). (Pubitemid 20088974)
77. Kunzmann V, Bauer E, Wilhelm M: γ/δ T-cell stimulation by pamidronate. N. Engl. J. Med. 340(9), 737-738 (1999).
78. Bottino C, Castriconi R, Pende D et al.: Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198(4), 557-567 (2003). (Pubitemid 37040390)
79. Ruggeri L, Capanni M, Urbani E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295(5562), 2097-2100 (2002). (Pubitemid 34229476)
80. Pietra G, Manzini C, Vitale M et al.: Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Int. Immunol. 21(7), 793-801 (2009).
81. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A: Surface NK receptors and their ligands on tumor cells. Semin. Immunol. 18(3), 151-158 (2006). (Pubitemid 43817561)
82. Ruggeri L, Capanni M, Casucci M et al.: Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94(1), 333-339 (1999). (Pubitemid 29300166)
83. + glioma cells: possible targets of immunotherapy. J. Neurooncol. 83(2), 121-131 (2007). n Discusses future targets of immunotherapy.
84. + NK T cell-mediated cytotoxicity. Int. J. Cancer 119(7), 1630-1637 (2006). (Pubitemid 44258769)
85. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6(5), 383-393 (2006).
86. Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 90, 1-50 (2006).